Tables
- Table 1– Summary evaluation report of the first 10 cases seeking expert advice through the European Respiratory Society/World Health Organization Consilium
Country of request origin Country of birth Sex Age years Clinical question to the expert Time to load request min Response time h Strain susceptibility P/EP Request for second opinion from the experts Clinician satisfied Experts' reported problems Italy Moldova F 29 Treatment regimen (after 9 months, still bacteriologically positive; when to stop it) 20 24 Susceptible P Yes Yes No Vietnam Vietnam F 14 Treatment regimen (drug choice) 20 24 MDR-TB P Yes Yes No Moldova Moldova M 34 Treatment regimen (drug choice) 20 24 XDR-TB P No Yes No India India F 12 Treatment regimen (drug choice) 20 24 Pre-XDR-TB P/EP (lymph node) No Yes No UK India F 19 Treatment regimen (drug choice) 20 24 XDR-TB EP (cervical and mediastinal lymph node) No Yes No UK Romania F 36 Treatment regimen and drug interactions 20 24 MDR-TB P No Yes No Italy Moldova F 28 Treatment duration (drug choice) 20 24 MDR-TB P No Yes No UK Somalia M 40 Treatment regimen, advice for monitoring the response and when to stop treatment 20 144# MDR-TB EP (mediastinal lymphadenopathy) No Yes No UK India M 35 Advice for management of cachexia, muscle wasting and possible surgery; confirmation of MDR-TB treatment plan 20 48 MDR-TB P No Yes No UK India F 32 Treatment regimen, advice for surgery, advice for PET 20 24 MDR-TB EP (chronic abscess on left thigh) No Yes No P: pulmonary; EP: extrapulmonary; F: female; M: male; MDR: multidrug-resistant; TB: tuberculosis; XDR: extensively drug-resistant; pre-XDR-TB: MDR-TB with additional resistant to a fluoroquinolone drug; PET: positron emission tomography. #: one expert took 6 days to respond.
Vol 43 Issue 1
Table of Contents
ERS/WHO Tuberculosis Consilium: reporting of the initial 10 cases
